Joseph Wekselblatt is an experienced scientist who has studied visual capabilities in various species for over a decade. He holds a Bachelor's degree in Cognitive Science from Brown University and a PhD in Neurobiology from the University of Oregon. After completing his PhD, he worked as a Postdoctoral Researcher at Caltech until 2023, when he joined Cyagen as a Senior Scientific Business Development Manager.

Dr. Jenny Shan (MD, PhD) brings decades of R&D experience from industry leaders like Regeneron, Moderna, J&J, EQRx, Apogee, and Curie.Bio.

Her expertise spans diverse modalities—antibodies, small molecules, ADCs, CAR-T, mRNA, siRNA, peptides, oligonucleotides, AAV, and gene editing—across oncology, immunology, cardiovascular, neuroscience, and ophthalmology.

As a strategic pipeline architect, Dr. Shan has advanced multiple programs from discovery to clinical development. She supported the IND and regulatory approvals for numerous biologics, contributing to blockbuster drugs such as Eylea, Dupixent, Carvykti, and Rybrevant.

Lucy is based in Boston and holds a B.S. in Biochemistry and Molecular Biology at the Wake Forest University. She earned her PhD in Biomolecular Pharmacology at Boston University, where she investigated how mRNA editing and posttranslational modifications influence glutamate receptor function and synaptic plasticity in sensory systems.

She now applying her scientific expertise to support drug-discovery partnerships and drive growth across the Northeast US market.